Clinical Trial Update: Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating tucatinib in combination with trastuzumab for patients with HER3-mutant and HER2-non-amplified metastatic or unresectable breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab (trastuzumab)
• Tucatinib (tucatinib)

Snippet

Sponsor: Institut Curie | Conditions: Metastatic Breast Cancer ( HER2 Negative), Unresectable Breast Cancer | Phase 2 | Status: RECRUITING